BCL2 and lung cancer: In a similar study, we used a complex liposomal drug delivery system containing anticancer drug doxorubicin and both MRP1 and BCL2 targeting antisense oligonucleotides for inhalation treatment in lung cancer cells.[27] While empty liposome, free antisense oligonucleotides and their combination treatment showed almost no influence on viability of lung cancer cells; liposome targeted to both MRP1 mRNA and BCL2 mRNA significantly inhibited the growth of the lung cancer cells.